Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trialHiddo J.L. Heerspink, Rey Isidto, Anna Maria Langkilde et al.|Nephrology Dialysis Transplantation|2019Cited by 216
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C. Wheeler, Hiddo J.L. Heerspink, Bergur V. Stefánsson et al.|Nephrology Dialysis Transplantation|2020Cited by 189
Heparanase-2 protects from LPS-mediated endothelial injury by inhibiting TLR4 signallingYulia Kiyan, Hermann Haller|Scientific Reports|2019Cited by 61
Calcium dobesilate reduces VEGF signaling by interfering with heparan sulfate binding site and protects from vascular complications in diabetic miceFlorence Njau, Hermann Haller|PLoS ONE|2020Cited by 27